143 related articles for article (PubMed ID: 9651600)
21. Reduced forward output states affect the left ventricular opacification of intravenously administered Albunex.
Gandhok NK; Block R; Ostoic T; Rawal M; Hickle P; Devries S; Feinstein SB
J Am Soc Echocardiogr; 1997; 10(1):25-30. PubMed ID: 9046490
[TBL] [Abstract][Full Text] [Related]
22. Optimizing albunex in the left ventricle: an analysis of the technical parameters of four ultrasound systems in canines and humans.
Block RJ; Brodsky L; Ostoic T; Fernandez A; Hickle P; Devries S; Bieniarz T; In M; Feinstein SB
J Am Soc Echocardiogr; 1996; 9(6):787-94. PubMed ID: 8943438
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the efficacy of two air-based contrast agents in dogs.
Uchimoto R; Niwa K; Tsuda N; Miyazawa T; Bräutigam M
Eur J Ultrasound; 2000 May; 11(2):127-33. PubMed ID: 10781661
[TBL] [Abstract][Full Text] [Related]
24. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial.
Cohen JL; Cheirif J; Segar DS; Gillam LD; Gottdiener JS; Hausnerova E; Bruns DE
J Am Coll Cardiol; 1998 Sep; 32(3):746-52. PubMed ID: 9741522
[TBL] [Abstract][Full Text] [Related]
25. Myocardial regional blood flow: quantitative measurement by computer analysis of contrast enhanced echocardiographic images.
Mor-Avi V; David D; Akselrod S; Bitton Y; Choshniak I
Ultrasound Med Biol; 1993; 19(8):619-33. PubMed ID: 8134967
[TBL] [Abstract][Full Text] [Related]
26. Intracoronary albunex. Its effects on left ventricular hemodynamics, function, and coronary sinus flow in humans.
Ten Cate FJ; Widimsky P; Cornel JH; Waldstein DJ; Serruys PW; Waaler A
Circulation; 1993 Nov; 88(5 Pt 1):2123-7. PubMed ID: 8222106
[TBL] [Abstract][Full Text] [Related]
27. The influence of Albunex on the pulmonary circulation in patients with pulmonary hypertension or left heart failure.
Zotz RJ; Genth S; Mitrovic V; Waaler A; Erbel R; Meyer J
Eur Heart J; 1996 Feb; 17(2):302-7. PubMed ID: 8732386
[TBL] [Abstract][Full Text] [Related]
28. [Improved left ventricular endocardial detection by a first generation contrast agent. Effect of dose].
Vargas F; Hilbert G; Gruson D; Chene G; Journot V; Diebold B; Roudaut R
Arch Mal Coeur Vaiss; 2000 Jan; 93(1):41-7. PubMed ID: 11227717
[TBL] [Abstract][Full Text] [Related]
29. [Assessment of myocardial perfusion with second harmonic imaging--using intravenous injection of Albunex and Levovist].
Hasegawa M; Saiki Y; Kayano H; Katagiri T
Nihon Rinsho; 1998 Apr; 56(4):903-8. PubMed ID: 9577606
[TBL] [Abstract][Full Text] [Related]
30. Loss of contrast intensity during systole in the left ventricular cavity with the use of the contrast agent Albunex. An analysis of its correlation with pressure and velocity.
Tiukinhoy S; Bhoopalam S; Winkelmann JW; Ammar K; Mangulabnan L; Reddy G; Fernandez A; Block R; Malhotra V; Feinstein S
Invest Radiol; 1996 Jul; 31(7):415-22. PubMed ID: 8818781
[TBL] [Abstract][Full Text] [Related]
31. Myocardial contrast echocardiography for assessment of myocardial perfusion at rest in a patient with left main coronary artery stenosis.
Hagendorff A; Pfeiffer D; Rother T; Becher H
Z Kardiol; 2003 Oct; 92(10):876-83. PubMed ID: 14579053
[TBL] [Abstract][Full Text] [Related]
32. The quantification of absolute myocardial perfusion in humans by contrast echocardiography: algorithm and validation.
Vogel R; Indermühle A; Reinhardt J; Meier P; Siegrist PT; Namdar M; Kaufmann PA; Seiler C
J Am Coll Cardiol; 2005 Mar; 45(5):754-62. PubMed ID: 15734622
[TBL] [Abstract][Full Text] [Related]
33. Albunex: a safe and effective commercially produced agent for myocardial contrast echocardiography.
Keller MW; Glasheen W; Kaul S
J Am Soc Echocardiogr; 1989; 2(1):48-52. PubMed ID: 2627424
[TBL] [Abstract][Full Text] [Related]
34. In vitro, animal, and human characterization of OPTISON infusions for myocardial contrast echocardiography.
Miller JJ; Tiemann K; Podell S; Doerr Stevens JK; Kuvelas T; Greener Y; Killam AL; Goenechea J; Dittrich HC; Becher H
J Am Soc Echocardiogr; 1999 Dec; 12(12):1027-34. PubMed ID: 10588777
[TBL] [Abstract][Full Text] [Related]
35. Differing susceptibility of echocardiographic contrast agents to adverse effects of biologic factors: multicenter, videodensitometric comparison of octafluoropropane-filled microspheres with air-filled microspheres for left ventricular opacification.
Hausnerova E; Gottdiener JS; Gould JJ; Pezzullo JC; Callahan JD; Cohen JL; Bruns DE; Kuvelas MT; West HE; Dittrich HC
J Am Soc Echocardiogr; 1999 Nov; 12(11):957-66. PubMed ID: 10552357
[TBL] [Abstract][Full Text] [Related]
36. Persistent opacification of the left ventricle and myocardium with a new echo contrast agent.
Strauss AL; Beller KD
Ultrasound Med Biol; 1999 Jun; 25(5):763-9. PubMed ID: 10414894
[TBL] [Abstract][Full Text] [Related]
37. Effect of static pressure on the disappearance rate of specific echocardiographic contrast agents.
Vuille C; Nidorf M; Morrissey RL; Newell JB; Weyman AE; Picard MH
J Am Soc Echocardiogr; 1994; 7(4):347-54. PubMed ID: 7917342
[TBL] [Abstract][Full Text] [Related]
38. Left ventricular opacification after peripheral venous injection of a modified albumin solution.
Lin SL; Lo JH; Mou CY; Ho SJ; Liu RH; Chan JY; Chang MS; Chiang HT; Chen CY
Int J Card Imaging; 1992; 8(1):53-61. PubMed ID: 1619305
[TBL] [Abstract][Full Text] [Related]
39. Intravenous Albunex during transesophageal echocardiography: quantitative assessment by videodensitometry and integrated backscatter analysis from unprocessed radiofrequency signals.
Angermann CE; Krüger TM; Junge R; Drewello R; Stempfle HU; Spes CH; Theisen K
J Am Soc Echocardiogr; 1995; 8(6):839-53. PubMed ID: 8611284
[TBL] [Abstract][Full Text] [Related]
40. [Polymer microparticles for right and left heart echocardiography and imaging myocardial perfusion after peripheral vein injection].
Zotz R; Genth S; Grande J; Walch A; Ziehn P; Krone V; Schuler G
Z Kardiol; 1996 Dec; 85(12):924-31. PubMed ID: 9082670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
